Introduction
Obesity is a chronic disease with a high prevalence and associated comorbidities, making it a growing global concern. GLP-1 agonists, used to treat type 2 diabetes, have been shown to be effective in promoting weight loss in preclinical and clinical studies. This review summarizes numerous studies conducted on the main drugs in the GLP-1 agonists class, outlining the maximum achievable weight loss.
Prevalence of Obesity Globally
Obesity is defined by a body mass index (BMI) of 30 kg/m2 or higher. The World Health Organization (WHO) reports that almost 60% of European adults are overweight or obese, with higher prevalence levels among men than women. Obesity is linked to increased mortality rates and is predicted to overtake smoking as the leading preventable risk factor for cancer in some countries.
Complications of Obesity
Obesity-related complications include type 2 diabetes, hypertension, ventilatory dysfunction, arthrosis, venous and lymphatic circulation diseases, depression, and others. These conditions have a negative impact on health and increase morbidity and mortality.
The Emergence of GLP-1 Receptor Agonists
GLP-1 receptor agonists (GLP1-RAs) have emerged as a promising treatment for obesity. These medications promote satiety, decrease hunger, and ultimately reduce food intake. They also improve glycemic control, induce weight loss, and offer cardio-metabolic and renal protection.
Liraglutide
Liraglutide, a daily injectable GLP-1 RA, has been shown to significantly reduce body weight in both diabetic and non-diabetic individuals. Clinical trials have demonstrated its efficacy in improving glycemic control and reducing cardiovascular risk factors.
Semaglutide
Semaglutide, another GLP-1 RA, has been extensively studied for its weight loss effects. Clinical trials have shown that semaglutide leads to significant and long-lasting weight loss, with improvements in cardiometabolic risk factors.
Tirzepatide
Tirzepatide, a dual agonist of GIP and GLP-1 receptors, has shown superior efficacy in improving glycemic control and inducing weight loss compared to other GLP-1 drugs. It represents a new vista for the treatment of obese individuals.
Lixisenatide and Exenatide
Lixisenatide and exenatide are other GLP-1 RAs that have been evaluated for their efficacy in weight management and glycemic control. These medications have shown significant reductions in body weight and improvements in glycemic control in clinical trials.
Conclusion
GLP-1 agonists have demonstrated significant efficacy in promoting weight loss and improving health outcomes in individuals with obesity, both with and without type 2 diabetes. These medications offer a promising approach to the management of obesity and its associated comorbidities.